These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 33072564)

  • 21. Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis.
    Matsukawa A; Rajwa P; Kawada T; Bekku K; Laukhtina E; Klemm J; Pradere B; Mori K; Karakiewicz PI; Kimura T; Chlosta P; Shariat SF; Yanagisawa T
    Int J Clin Oncol; 2024 Jun; 29(6):716-725. PubMed ID: 38582807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world.
    Lu Y; Jiang J; Yang G; Ding H; Zheng Q; Ji L; Wang Y; Dong Z; Zhai Z; Tian J; Zhang Y; Wang J; Yang L; Wang Z
    Front Oncol; 2024; 14():1324181. PubMed ID: 38699643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What kind of patients with castration-naïve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis.
    Sun G; Zhang X; Chen J; Liao B; Liu Z; Zhao J; Gao AC; Yang Y; Shu K; Liu J; Zhao P; Shen P; Zeng H
    Urol Oncol; 2018 Dec; 36(12):505-517. PubMed ID: 30316578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer].
    Wenzel M; Hoeh B; Chun FKH; Mandel P
    Urologie; 2023 Apr; 62(4):360-368. PubMed ID: 36763112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral chemotherapeutic agents in metastatic hormone-sensitive prostate cancer: A network meta-analysis of randomized controlled trials.
    Lee YS; Kim SH; Tae JH; Chang IH; Kim TH; Myung SC; Kim M; Nguyen TT; Choi J; Kim JH; Kim JW; Choi SY
    Prostate Int; 2023 Sep; 11(3):159-166. PubMed ID: 37745904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis.
    Maiorano BA; De Giorgi U; Roviello G; Messina C; Altavilla A; Cattrini C; Mennitto A; Maiello E; Di Maio M
    ESMO Open; 2022 Oct; 7(5):100575. PubMed ID: 36152486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Cost-Effectiveness Analysis of Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
    Sung WWY; Choi HCW; Luk PHY; So TH
    Front Oncol; 2021; 11():627083. PubMed ID: 33718198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
    McNamara M; Sweeney C; Antonarakis ES; Armstrong AJ
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis.
    Wang L; Hong H; Alexander GC; Brawley OW; Paller CJ; Ballreich J
    Value Health; 2022 May; 25(5):796-802. PubMed ID: 35500949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
    Roy S; Sayyid R; Saad F; Sun Y; Lajkosz K; Ong M; Klaassen Z; Malone S; Spratt DE; Wallis CJD; Morgan SC
    Eur Urol Oncol; 2022 Oct; 5(5):494-502. PubMed ID: 35811293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination therapy in metastatic castration sensitive prostate cancer: A Systematic review and network meta-analysis.
    Kumar J; Alam MU; Jazayeri SB; Tanneru K; Bazargani S; Shastri C; Gautam S; Koochekpour S; Shukla S; Bandyk M; Costa J; Balaji KC
    Indian J Urol; 2022; 38(3):220-226. PubMed ID: 35983120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis.
    Fallara G; Robesti D; Nocera L; Raggi D; Marandino L; Belladelli F; Montorsi F; Malavaud B; Ploussard G; Necchi A; Martini A
    Cancer Treat Rev; 2022 Nov; 110():102441. PubMed ID: 35939976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hormone naïve metastatic prostate cancer: How to treat it?
    Østergren PB; Ternov KK; Jensen CFS; Jakobsen H; Lindberg H; Sønksen J; Fode M
    Arch Esp Urol; 2019 Mar; 72(2):192-202. PubMed ID: 30855021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer.
    Barbier MC; Tomonaga Y; Menges D; Yebyo HG; Haile SR; Puhan MA; Schwenkglenks M
    PLoS One; 2022; 17(11):e0277282. PubMed ID: 36327294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
    Roy S; Fervaha G; Spratt DE; Sun Y; Kishan AU; Loblaw A; Malone S; Ong M; Saad F; Wallis CJD; Morgan SC
    Eur Urol; 2024 Jul; 86(1):10-17. PubMed ID: 38570246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis.
    Rajwa P; Pradere B; Gandaglia G; van den Bergh RCN; Tsaur I; Shim SR; Yanagisawa T; Laukhtina E; Mori K; Mostafaei H; Quhal F; Bryniarski P; Compérat E; Roubaud G; Massard C; Merseburger AS; Leapman MS; Spratt DE; Saad F; Joniau S; D'Amico AV; Briganti A; Shariat SF; Ploussard G;
    Eur Urol; 2022 Jul; 82(1):82-96. PubMed ID: 35465985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials.
    Wang Y; Zhang H; Shen W; He P; Zhou Z
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1751-1768. PubMed ID: 29797220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer.
    Sathianathen NJ; Alarid-Escudero F; Kuntz KM; Lawrentschuk N; Bolton DM; Murphy DG; Kim SP; Konety BR
    Eur Urol Oncol; 2019 Nov; 2(6):649-655. PubMed ID: 31411985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Short-Term Outcomes and Safety Profiles between Androgen Deprivation Therapy+Abiraterone/Prednisone and Androgen Deprivation Therapy+Docetaxel in Patients with
    Park DJ; Kwon TG; Park JY; Joung JY; Ha HK; Jeon SS; Hong SH; Park S; Lee SH; Cho JS; Park SW; Kwon SY; Jo JK; Park HS; Lee SC; Kwon DD; Kim SI; Park SH; Kim S; Jeong CW; Kwak C; Choi SH;
    World J Mens Health; 2024 Jul; 42(3):620-629. PubMed ID: 38164028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.